ERBB2 and breast cancer: Of note, TP53 was differentially mutated in Her2-positive (n = 120) versus Her2-negative (n = 985) tumors in BC TCGA with 46.7% of Her2-positive tumors carrying a TP53 mutation versus 29.4% of Her2-negative tumors (Table 4a, p = 0.0002).